Introduction
The scientific and medical communities have long recognized that muscle weakness is a major risk factor for physical limitations, outright physical disability, and early death in older adults. 1 It was long assumed that age-related loss of lean mass (ie, sarcopenia) was the primary contributor to weakness.
This led to a number of pharmaceutical companies pursuing compounds that mechanistically act on muscle (eg, hypertrophy-inducing myostatin inhibitors) with the goal being to enhance muscle and physical function. 2 Most of these have failed to enhance muscle strength and physical function, in part because of the multiple factors associated with muscle strength and physical function that extend well beyond muscle mass. For instance, longitudinal data clearly demonstrate that loss of strength is only modestly associated with loss of mass in older adults. 3 Given that muscle force production is driven both by skeletal muscle size and quality as well as the nervous system, 4 this cross-sectional study specifically examined the role of the nervous system in clinically meaningful, age-related weakness. Specifically, we sought to determine whether older adults with clinically meaningful weakness exhibit impairments in their nervous systems' (peripheral and central) ability to activate their lower extremity muscles compared with their stronger counterparts. Here, we calculated the degree of voluntary inactivation (VIA) by comparing voluntary and electrically stimulated muscle forces. 5 While this does not give insight about where in the nervous system impairment may occur, it does provide insight into whether the nervous system may have a global involvement in weakness.
Methods
The Ohio University institutional review board approved this cross-sectional study, and participants provided written informed consent. From July 2015 to October 2018, 67 community-dwelling older adults without overt neurological disorders (mean [SD] age, 75.2 [6.9] years; 44 [66%] women) performed maximal isokinetic leg extension strength tests (BioDex System 4) 6 and were subsequently classified as weak, modestly weak, or strong based on strength, identifying older adults at high and low risk of developing severe mobility limitations. 6 We quantified VIA using the doublet interpolation technique similar to our prior work by supramaximally electrically stimulating the quadriceps muscle group (DS7AH; Digitimer) during a maximal voluntary effort with any increment in force evoked by the stimulus indicating deficits in voluntary activation. 5 Estimates of lean mass were obtained from a whole-body dual-energy radiographic absorptiometry scan (Discovery W; Hologic). Group differences were examined using analysis of variance with sex entered as a factor, and Sidak post hoc tests were conducted on any significant analyses of variance using SPSS statistical software, version 25 (IBM). Two-tailed P Յ .05 was considered statistically significant. (Table) . With regard to VIA capacity, there was no group × sex interaction (F 2,60 = 0.982; P = .38), but a group main effect was noted (F 2,60 = 4.010; P = .02). Post hoc testing indicated that the weak older adults exhibited significantly higher levels of VIA than the strong older adults (14.2% vs 7.1%; difference, −7.1%; 95% CI, −12.3% to −1.9%; P = .008) (Figure) . 
